

Medical Drug Clinical Criteria

Subject:	Akynzeo (fosnetupitant and palonosetron) for injection		
Document #:	CC-0074	Publish Date:	<u>12/18/2023</u> <u>12/23/2024</u>
Status:	Revised <u>Reviewed</u>	Last Review Date:	<u>11/17/2023</u> <u>11/15/2024</u>

Table of Contents

Overview	Coding	References
Clinical criteria	Document history	

Overview

This document addresses the use of Akynzeo (fosnetupitant and palonosetron) for injection. Akynzeo is a combination of palonosetron, a serotonin 3 (5-HT₃) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist. Palonosetron prevents nausea and vomiting during the acute phase, and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Akynzeo for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Akynzeo (fosnetupitant and palonosetron) for injection

Requests for Akynzeo (fosnetupitant and palonosetron) for injection may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual is using for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy (NCCN 1, Label); **AND**
- III. Individual is using in combination with dexamethasone.

Akynzeo (fosnetupitant and palonosetron) for injection may not be approved when the above criteria are not met and for all other indications.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg [Akynzeo]

ICD-10 Diagnosis

R11.0-R11.2 Nausea and vomiting

C00.0-C96.9 Malignant neoplasms

D00.00-D09.9 In situ neoplasms

Z51.11 Encounter for antineoplastic chemotherapy

Document History

Reviewed: 11/15/2024

Document History:

- 11/15/2024 – Annual Review: No change. Coding Reviewed: No changes.
- 11/17/2023 – Annual Review: add moderate emetogenicity. Coding Reviewed: No changes.
- 11/18/2022 – Annual Review: No changes. Coding Reviewed: No changes.
- 11/19/2021 – Annual Review: No change. Coding reviewed: No changes.
- 11/20/2020 – Annual Review: No changes. Coding Reviewed: No changes.
- 11/15/2019 – Annual Review: Minor wording and formatting changes. Coding Review: Added ICD-10 dx codes C00-C96.9, D00.00-D09.9, Z51.11, Z85.00-Z85.9.
- 11/26/2018 – Deleted HCPCS codes C9033.
- 11/16/2018 – Annual Review: Annual review. No changes.
- 11/09/2018 – Added ICD-10 dx R11.0-R11.2.
- 11/02/2018 – Added HCPCS codes: C9033, J1454. C9033 newly effective 10/01/2018.
- 08/17/2018 – Select Review: Add new PA and QL for Akynzeo (fosnetupitant and palonosetron) for injection.

References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2024. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on October 2, 2024.
 - a. Antiemesis. V2.2024. Revised September 27, 2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association